Although initially given as replacement therapy for patients with primary and secondary immunodeficiency states, intravenous immunoglobulin (IVIg) has proven to be effective in the treatment of various autoimmune and inflammatory disorders. This success has led to a dramatic increase in the use of IVIg, with its use as an antiinflammatory agent now vastly surpassing its use in the treatment of immunodeficiencies. Even so, the basis for the antiinflammatory activity of IVIg remains unclear.
Search results for: macrophage
Link between Autoimmunity and Environmental Exposure Needs Further Research
Rheumatology needs further cost-effective and validated methods to track the connection between environmental exposure and autoimmune diseases, including research on phenotypes, genotypes, the synergy between multiple infectious and noninfectious exposures, the timing of exposure, and the mechanisms involved, according to presenters of “Impact of Environmental Health on Autoimmunity,” a session here at the 2011 ACR/ARHP Annual Scientific Meeting held in Chicago in November 2011.
Old Drugs Can Learn New Tricks
Methotrexate and its mechanism of action
The Microbiome
A voyage to (our inner) Lilliput
T Cells in Systemic Lupus Erythematosus
Progress toward targeted therapy
What Fat Does to Arthritis
The role of adipokines in the pathogenesis of rheumatic diseases
How a Nuclear Molecule Alarms the Immune System
The role of HMGB1 in the pathogenesis of lupus nephritis
A&R Abstracts – HMGB1
For Further Reading
A Meeting of the Minds for RA Research
REF investigators gather to share research progress and trade advice
How Energy Shifts Lead to Systemic Illness
The impact of adaptive energy programs on the manifestations of chronic inflammatory disease
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- 27
- Next Page »